Careers

The ADRI is a state-of-the-art research facility promoting an environment of innovation, collaboration and research excellence in asbestos-related diseases.

Current Positions

There are currently no vacancies available.

However, we are always keen to meet energetic and talented professionals who would like to join our team.

If you wish to be considered for any future positions, please send your CV and covering letter to: info@adri.org.au

Postgraduate Studies

Australia has the world's highest incidence of malignant mesothelioma per capita, with more than 700 new cases diagnosed each year, and it has been estimated that there were at least another 1,500 Australians with lung cancer caused by asbestos. This is a tragic consequence of the intensive use of asbestos and its products in Australia in the previous century and is estimated that as many as one in three homes in Australia contains asbestos. As a response to this legacy, the Asbestos Diseases Research Institute (ADRI) was opened in 2009 and is a state-of-the-art medical research facility dedicated to the prevention and treatment of asbestos-related diseases, particularly asbestos-related lung cancer and malignant mesothelioma.

Under the leadership of Professor Ken Takahashi, ADRI’s research framework focuses on:

  1. Fundamental Biology Research;
  2. Clinical Sciences; and
  3. Public Health and Prevention (including themes on epidemiology).

We are currently seeking high calibre students to pursue PhD or Masters studies in asbestos-related diseases research.

How To Apply

All applications are to be submitted to E/Professor Takahashi for consideration info@adri.org.au. As ADRI is a not-for-profit medical research organisation, it is unlikely that a research program will have the funds to take on a postgraduate student without scholarship funding. However, there are various scholarship schemes on offer and can be found through The Good Universities Guide.

Projects Available

  1. Prevention of Asbestos-Related Diseases
  2. To discover biomarkers that better facilitate early diagnosis of mesothelioma
  3. Pre-clinical anti-mesothelioma discovery